MEDIA

Media Inquiries

Investors@OncoSec.com

855-662-6732

Press Releases

VIEW ALL PRESS RELEASES

Video Feed

3D MOA Animation video

✕

OncoSec's VLA 3D MOA Animation

✕

TAVO Demonstration with Dr Algazi

✕

OncoSec at 2020 BIO CEO Panel

✕

Tumor Immunogenicity

✕

IAD Reel

✕

IAD Robert Andtbacka, M.D.

✕

Social Media

Twitter Feed

OncoSec Medical@OncoSec·
10h

On Sunday, September 19th, OncoSec will support the #MelanomaResearchFoundation @CureMelanoma and #Melanoma patients, survivors, & supporters at the #NewJerseyMilesForMelanoma5K! Click here to learn more about the event and how to get involved: https://bit.ly/3DhFtPb

OncoSec Medical@OncoSec·
16 Sep

We are proud to be supporting @touchbbca at their Magic Touch #Anniversary Celebration on Sunday, September 19. Learn more about this event & join us in recognizing TOUCH’s ongoing efforts in building a movement to eradicate #BlackBreastCancer: https://bit.ly/3kPp2BA

OncoSec Medical@OncoSec·
8 Sep

On Saturday, September 11th, join OncoSec in supporting the #MelanomaResearchFoundation @CureMelanoma & #Melanoma patients & survivors by registering for the #NewEnglandMilesForMelanoma5K! Click here to learn more about the event and register: https://bit.ly/3myrezy

OncoSec Medical@OncoSec·
3 Aug

Evidence of anti-tumor activity w/ #AbscopalEffect from our Phase II #Melanoma program data paved the way for the expansion of our #ImmunoOncologyPipeline, including a study designed to test our platform technology in #TNBC. Learn more: https://bit.ly/36CT44O

Featured Articles

Melanoma Research Alliance

From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate

PharmaVoice

Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter

Annals of Oncology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Clinical Cancer Research

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.